Show simple item record

dc.contributor.authorTolppanen, Anna-Maija
dc.contributor.authorTaipale, Heidi
dc.contributor.authorKoponen, Marjaana
dc.contributor.authorLavikainen, Piia
dc.contributor.authorTanskanen, Antti
dc.contributor.authorTiihonen, Jari
dc.contributor.authorHartikainen, Sirpa
dc.date.accessioned2016-10-06T05:54:47Z
dc.date.available2016-10-06T05:54:47Z
dc.date.issued2016
dc.identifier10.1136/bmjopen-2016-012100fi_FI
dc.identifier.citationTolppanen, A.-M., Taipale, H., Koponen, M., Lavikainen, P., Tanskanen, A., Tiihonen, J., & Hartikainen, S. (2016). Cohort profile: the Finnish Medication and Alzheimer’s disease (MEDALZ) study. BMJ Open, 6(7), e012100. http://doi.org/10.1136/bmjopen-2016-012100fi_FI
dc.identifier.issn2044-6055
dc.identifier.urihttps://erepo.uef.fi/handle/123456789/143
dc.descriptionArticle
dc.description.abstractPurpose The aim of the Medicine use and Alzheimer's disease (MEDALZ) study is to investigate the changes in medication and healthcare service use among persons with Alzheimer's disease (AD) and to evaluate the safety and effectiveness of medications in this group. This is important, because the number of persons with AD is rapidly growing and even though they are a particularly vulnerable patient group, the number of representative, large-scale studies with adequate follow-up time is limited. Participants MEDALZ contains all residents of Finland who received a clinically verified diagnosis of AD between 2005 and 2011 and were community-dwelling at the time of diagnosis (N=70 719). The diagnosis is based on the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCS-ADRDA) and Diagnostic and Statistical Manual Fourth Edition (DSM-IV) criteria for Alzheimer's disease. The cohort contains socioeconomic data (education, occupational status and taxable income, 1972–2012) and causes of death (2005–2012), data from the prescription register (1995–2012), the special reimbursement register (1972–2012) and the hospital discharge register (1972–2012). Future updates are planned. The average age was 80.1 years (range 34.5–104.6 years). The majority of cohort (65.2%) was women. Currently, the average length of follow-up after AD diagnosis is 3.1 years and altogether 26 045 (36.8%) persons have died during the follow-up. Findings Altogether 53% of the cohort had used psychotropic drugs within 1 year after AD diagnoses. The initiation rate of for example, benzodiazepines and related drugs and antidepressants began to increase already before AD diagnosis. Future plans We are currently assessing if these, and other commonly used medications are related to adverse events such as death, hip fractures, head injuries and pneumonia.fi_FI
dc.language.isoenfi_FI
dc.publisherBMJ Publishing Group Ltdfi_FI
dc.relation.ispartofseriesBMJ Open
dc.relation.urihttp://doi.org/10.1136/bmjopen-2016-012100fi_FI
dc.rightsCC BY http://creativecommons.org/licenses/by/4.0/
dc.titleCohort profile: the Finnish Medication and Alzheimer's disease (MEDALZ) studyfi_FI
dc.typehttp://purl.org/eprint/type/JournalArticle
dc.rights.licenseCC BY http://creativecommons.org/licenses/by/4.0/’
dc.description.versionPublisher's pdffi_FI
dc.contributor.departmentFaculty of Health Sciences
dc.contributor.departmentSchool of Pharmacy, Activities
dc.contributor.departmentSchool of Medicine / Clinical Medicine
uef.solecris.id41078001
eprint.statushttp://purl.org/eprint/status/PeerReviewedfi_FI
dc.type.publicationinfo:eu-repo/semantics/article
dc.rights.accessrights© Authors
dc.relation.doi10.1136/bmjopen-2016-012100
dc.description.reviewstatushttp://purl.org/eprint/status/PeerReviewed
dc.relation.articlenumbere012100
dc.relation.issn2044-6055
dc.relation.issue7
dc.relation.volume6


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record